Health Affairs, 25, no. 2 (2006): 313-324
doi: 10.1377/hlthaff.25.2.313
© 2006 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Figures Only
* Full Text (HTML)
* Reprint (PDF)
* Technical Appendix
* Media/Policy Briefing
* Interview with lead author
* Submit a response to this article
* Comments: View responses
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in Web of Science
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Web of Science (6)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Ridley, D. B.
* Articles by Moe, J. L.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Ridley, D. B.
* Articles by Moe, J. L.
Related Collections
* Health Promotion/Disease Prevention
* Health Reform
* International Issues
* Legal/Regulatory Issues
* Business Of Health
* Pharmaceuticals
* Public Health
* Research And Technology
* Health Spending
* Consumer Issues
* Related Blog Posts

Drugs/Vaccines

Developing Drugs For Developing Countries

David B. Ridley, Henry G. Grabowski and Jeffrey L. Moe

Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments for neglected diseases receive a "priority review voucher." The voucher could save an average of one year of U.S. Food and Drug Administration (FDA) review and be sold by the developer to the manufacturer of a blockbuster drug. In a well-functioning market, the voucher would speed access to highly valued treatments. Thus, the voucher could benefit consumers in both developing and developed countries at relatively low cost to the taxpayer.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


Related Blog Posts:

GLOBAL HEALTH: The Impact Of A Health Affairs Paper

This article has been cited by other articles:


Home page
Health Aff (Millwood)Home page
P. Musgrove and P. J. Hotez
Turning Neglected Tropical Diseases Into Forgotten Maladies
Health Aff., November 1, 2009; 28(6): 1691 - 1706.
[Abstract] [Full Text] [PDF]


Home page
Public Health EthicsHome page
J. Sonderholm
A Reform Proposal in Need of Reform: A Critique of Thomas Pogge's Proposal for How to Incentivize Research and Development of Essential Drugs
Public Health Ethics, July 3, 2009; (2009) php017v1.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. Moe, H. Grabowski, D. Ridley, and A. S. Kesselheim
FDA Review Vouchers
N. Engl. J. Med., February 19, 2009; 360(8): 837 - 838.
[Full Text] [PDF]


Home page
NEJMHome page
A. S. Kesselheim
Drug Development for Neglected Diseases -- The Trouble with FDA Review Vouchers
N. Engl. J. Med., November 6, 2008; 359(19): 1981 - 1983.
[Full Text] [PDF]


Home page
Public Health EthicsHome page
M. Ravvin
Incentivizing Access and Innovation for Essential Medicines: A Survey of the Problem and Proposed Solutions
Public Health Ethics, July 1, 2008; 1(2): 110 - 123.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
M. K. Kyle and D. B. Ridley
Would Greater Transparency And Uniformity Of Health Care Prices Benefit Poor Patients?
Health Aff., September 1, 2007; 26(5): 1384 - 1391.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
J. Fisher Wilson
Alterations in processes and priorities needed for new drug development.
Ann Intern Med, November 21, 2006; 145(10): 793 - 796.
[Full Text] [PDF]

Comments:

Read all Comments

Benefits of Expedited Review Likely Overstated
Ian D. Spatz
Health Affairs, 13 Mar 2006 [Full text]
Global Disease Burdens
Kevin Outterson
Health Affairs, 15 Mar 2006 [Full text]
A Rights-Based Approach to Drug Development for Neglected Diseases
Sonal Singh
Health Affairs, 30 Mar 2006 [Full text]
Response from the Authors
David B. Ridley, et al.
Health Affairs, 22 May 2006 [Full text]